Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Tomivosertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Tomivosertib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tegoprubart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Tegoprubart: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
25 valent pneumococcal conjugate vaccine (Inventprise) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
25 valent pneumococcal conjugate vaccine (Inventprise): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
Latanoprost Liposomal Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Latanoprost Liposomal: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
LB-100 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
LB-100: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Nespacel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Nespacel: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
GRAd-COV2 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
GRAd-COV2: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
DA-9801 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
DA-9801: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Avid Radiopharmaceuticals, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Avid Radiopharmaceuticals, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
Latest Hotspot
8 min read
Sirna Therapeutics, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Sirna Therapeutics, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
8 min read
DISC-0974 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
DISC-0974: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
ARIUS Research, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
ARIUS Research, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.